A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

286 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-10

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to verify the safety and efficacy of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters Swide®

NCT06024525

Coronary Artery Disease

NOT_YET_RECRUITING NA

Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents

NCT02528474

Coronary Artery Disease

TERMINATED NA

Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions

NCT03223974

Coronary Disease

COMPLETED NA

Clinical Efficacy and Safety of a Prospective, Multicenter Drug Coated Balloon for Left Main Artery Disease in China

NCT04641468

Coronary Diseases Left Main Coronary Artery Disease Bifurcation Lesions

UNKNOWN NA

Randomized Comparison of DCB for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

NCT02648334

Angioplasty, Balloon Catheterization, Peripheral Popliteal Artery +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study include a small vessel cohort and a very small vessel cohort. In the small vessel cohort, patients with visually estimated reference vessel diameters(RVDs)≥2.0 and ≤2.75mm were randomly assigned to the Coronary Drug Coated Balloon Catheter Used in Small Vessels of Lepu Medical or the Restore DEB in a 1:1 ratio. The study was powered to detect the noninferiority of the DCB of Lepu Medical versus the Restore DEB for a primary endpoint of in-segment late lumen loss(LLL) at 9 months.

In the very small vessel cohort, patients with RVD≥1.75 and\<2.0mm were treated with the DCB of Lepu Medical of an appropriate size.

All subjects will been followed up for 2 years to observe the occurrence of adverse events, so as to make an accurate and reliable evaluation of the safety of drug coated balloon catheters for coronary small vessels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

small vessel cohort: DCB of Lepu Medical

receiving the treatment with DCB of Lepu Medical(dimeter≥2.00 mm) in small vessel cohort

Group Type EXPERIMENTAL

DCB of Lepu Medical(dimeter≥2.00 mm)

Intervention Type DEVICE

subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)

small vessel cohort:Restore DEB

receiving the treatment with Restore DEB in small vessel cohort

Group Type ACTIVE_COMPARATOR

Restore DEB

Intervention Type DEVICE

subjects receiving Restore DEB

very small vessel cohort: DCB of Lepu Medical

receiving the treatment with DCB of Lepu Medical(dimeter\<2.00 mm) in very small vessel cohort

Group Type OTHER

DCB of Lepu Medical(dimeter<2.00 mm)

Intervention Type DEVICE

subjects receiving DCB of Lepu Medical(dimeter\<2.00 mm)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DCB of Lepu Medical(dimeter≥2.00 mm)

subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)

Intervention Type DEVICE

Restore DEB

subjects receiving Restore DEB

Intervention Type DEVICE

DCB of Lepu Medical(dimeter<2.00 mm)

subjects receiving DCB of Lepu Medical(dimeter\<2.00 mm)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary small vessels RESTORE Paclitaxel releasing coronary balloon catheter Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary very small vessels

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age must be 18-80 years, males or females.
* Subject with stable angina, or unstable angina, or recent myocardial infarction (myocardial infarction occurred more than 7 days before enrolled into the group), or asymptomatic myocardial ischemia with evidence
* Coronary angiopathy in situ with stenosis of more than 70% with visually estimated (or more than 50% combined with symptoms of ischemia, TIMI ≥ 1) in a vessel with visually estimated reference vessel diameter (RVD) ≥ 2.0 mm and ≤ 2.75 mm in small vessel group,and ≤ 26 mm in length or RVD ≥ 1.75 mm and \< 2.0 mm in very small vessel group, and ≤ 16 mm in length.
* Target small vessel lesions are located on one or two different coronary arteries (RCA / LAD/ LCX). The number of target small vessel lesions on each coronary artery is no more than one, and each target small vessel lesion can only be treated with one test instrument
* The number of non-target lesions requiring early interventional treatment is no more than two, and the distance between them and target lesions must be \> 10 mm; Successful treatment of non target lesions is required before subjects are randomized and the test equipment(DCB) cannot be used for the treatment.
* Subject can receive any type of coronary revascularization (including balloon angioplasty, stent implantation or coronary artery bypass grafting)
* Subject can understand the study objectives and voluntarily participate in and sign the informed consent; subject must agree to clinical follow-up and angiographic follow-up at 9 months.

Exclusion Criteria

* AMI within 1 week.
* In stent restenosis, complete occlusion or severe calcification (unable to pre expand successfully with balloon)
* Left main artery disease or bifurcation disease with diameter \>2.00mm requiring interventional treatment
* Evidence of massive thrombi in the target vessels
* Severe heart failure (NYHA IV)
* Severe renal failure (subject with GFR \< 30ml / min or undergoing hemodialysis)
* Subject with vein graft restenosis after bypass surgery or severe heart valve disease
* Pregnant or nursing subjects
* Life expectancy less than 12 months
* Subject with bleeding tendency, history of active peptic ulcer, suffered stroke within the past 6 months, contraindications of antiplatelet preparation and anticoagulant treatment
* Subject is currently participating in another investigational drug or device study that has not yet completed its primary endpoint.
* Subject has undergone heart transplantation
* Known allergy to aspirin, clopidogrel, heparin, contrast media, and paclitaxel.
* The investigator judged that the subject's compliance is poor and can not complete the study as required.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yida Tang

Role: STUDY_CHAIR

Peking University Third Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.